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Background: The tumor suppressor protein phosphatase 2A (PP2A) is frequently inactivated in human cancer and
phosphorylation of its catalytic subunit (p-PP2A-C) at tyrosine-307 (Y307) has been described to inhibit this
phosphatase. However, its molecular and clinical relevance in colorectal cancer (CRC) remains unclear.
Methods: p-PP2A-C Y307 was determined by immunoblotting in 7 CRC cell lines and 35 CRC patients. CRC
cells were treated with the PP2A activator forskolin alone or combined with the PP2A inhibitor okadaic acid,
5-ﬂuorouracil and oxaliplatin. We examined cell growth, colonosphere formation, caspase activity and AKT
and ERK activation.
Results: PP2A-C was found hyperphosphorylated in CRC cell lines. Forskolin dephosphorylated and activated
PP2A, impairing proliferation and colonosphere formation, and inducing activation of caspase 3/7 and changes
in AKT and ERK phosphorylation. Moreover, forskolin showed additive effectswith 5-ﬂuorouracil and oxaliplatin
treatments. Analysis of p-PP2A-C Y307 in primary tumors conﬁrmed the presence of this alteration in a subgroup
of CRC patients.
Conclusions: Our data show that PP2A-C hyperphosphorylation is a frequent event that contributes to PP2A inhi-
bition in CRC. Antitumoral effects of forskolin-mediated PP2A activation suggest that the analysis of p-PP2A-C
Y307 status could be used to identify a subgroup of patients who would beneﬁt from treatments based on
PP2A activators.© 2014 Elsevier B.V. All rights reserved.1. Introduction
Colorectal cancer (CRC) is the third most common human cancer
and a major cause of morbidity and mortality throughout the world
[1]. CRC survival rates are similar between males and females, and the
5-year survival rate considering patients diagnosed from 2003 to 2009
is currently around 70%. Moreover, only 40% of CRC patients are diag-
nosed at a local stage of the disease, showing a 5-year survival rate of
90%. However, survival decreases to 70.4% and 12.5% in those CRC
cases with regional and distant metastasis at diagnosis, respectivelylogy Division, Health Research
Fundacion Jimenez Diaz”, Avda.
800 (2824).
al Oncology Division, Health
y Hospital “Fundacion Jimenez
+34 915504800.
oncillas@gmail.com[2]. Despite progressive advances in the treatment of metastatic CRC
through the development of novel cytotoxic drugs, patient outcomes
are still very poor [3]. Therefore, it is necessary to better understand
the molecular basis of this disease in order to develop alternative ther-
apeutic strategies that may improve patient outcomes [4].
The loss of a correct equilibrium between kinase and phosphatase
activities is a key event in cell transformation that deregulates normal
cell homeostasis [5]. In fact, an aberrant kinase activity has been report-
ed in many tumor types and different monotherapies based on kinase
inhibitors have been incorporated into anticancer protocols. However,
the potential therapeutic value of phosphatase activating drugs remains
in comparison mostly unknown.
Protein phosphatase 2A (PP2A) is a major serine/threonine phos-
phatase that plays a key role as a tumor suppressor regulating many
signaling pathways with a high relevance in human cancer through
modulating the phosphorylation status of proteins such as AKT or ERK
[6–9]. PP2A has been reported to be frequently inactivated in cancer
cells by different molecular mechanisms including the phosphorylation
1824 I. Cristóbal et al. / Biochimica et Biophysica Acta 1842 (2014) 1823–1829of its catalytic subunit [PP2A-C] at Y307 [8–12]. In addition, its pharma-
cological activation has shown promising therapeutic effects, especially
in leukemias [13–15]. Although several observations suggest that
PP2A represents a drugable tumor suppressor also in CRC, it remains
necessary to fully clarify the relevance of the different PP2A inhibitory
mechanisms and the antitumor efﬁcacy of PP2A activating drugs in
this disease. In fact, low prevalent mutations affecting PP2A have been
reported in CRC and our group has recently reported that PP2A inhibi-
tion is a common event in CRC and that its restoration using FTY720
(a FDA-approved immunosuppressor used in multiple sclerosis treat-
ment with PP2A activating properties) shows promising antitumor
effects [13,16–20]. Moreover, this phosphatase is involved in resistance
of CRC cells to antiangiogenesis therapies [21,22]. Therefore,we hypoth-
esized that PP2A would be commonly inhibited in CRC and that its
phosphorylation on PP2A-C Y307 could represent a novel inhibitory
mechanism with molecular and therapeutic relevance in this disease.
In this report, we show that PP2A-C hyperhosphorylation contrib-
utes to inactivate PP2A in CRC cells. Interestingly, we observed that
forskolin treatment dephosphorylated and increased PP2A activity,
impairing proliferation and colonosphere formation, and inducing acti-
vation of caspase 3/7 and changes in the phosphorylation status of AKT
and ERK. Interestingly, forskolin showed additive effects with either 5-
ﬂuorouracil or oxaliplatin treatments. Moreover, we conﬁrmed that
PP2A-C is hyperphosphorylated in a subgroup of CRC patient samples,
which indicates the potential therapeutic use of PP2A-C dephosphory-
lating drugs in those patients, alone or in combination with standard
chemotherapy agents.
2. Materials and methods
2.1. Cell cultures
The human CRC cell lines RKO (ATCC CRL-2577), LoVo (ATCC CCL-
229), SW480 (ATCC CCL-228), WiDr (ATCC CCL-218), DLD-1 (ATCC
CCL-221), HT-29 (ATCCHTB-38) and SW620 (ATCC CCL-227)were pur-
chased from American Type Culture Collection (ATCC). Authentication
was done by the authors (LGC Standards). Cell lines were maintained
in RPMI-1640 (Invitrogen) with 10% fetal bovine serum (FBS) and
were grown at 37 °C in a 5% CO2 atmosphere. Media were supplement-
ed with penicillin G (100 U/ml), and streptomycin (0.1 mg/ml). Cells
were treated with the following reagents: 5-FU (1 μM) (Sigma),
oxaliplatin (LOHP) (1 μM) (Sigma), forskolin (40 μM) (Calbiochem)
and okadaic acid (OA) (2.5 nM) (Calbiochem). Forskolin has previously
been reported to activate PP2A in association with its dephosphoryla-
tion [12], and OA has been used in this work at a concentration that in-
hibits PP2A but no other phosphatases [23].
2.2. Patient samples
The study comprised fresh frozen samples of 35 patients with
CRC. Primary colorectal tissues were surgical resection specimens
from CRC tumors obtained from Fundacion Jimenez Diaz Biobank
(BFJD, Madrid). TNM (Tumor, Node, Metastases) staging was classiﬁed
using the 7th American Joint Committee on Cancer (AJCC) staging sys-
tem for CRC. Clinical data were collected from medical clinical records
by an oncologist. Paired normal mucosa obtained from each patient
was used as control. A pathologist conﬁrmed that primary tumor tissues
used in this work contained greater than 70% tumoral component. In-
formed consent was obtained from all patients. The ethical committee
and institutional review board from the University Hospital “Fundacion
Jimenez Diaz” approved the project.
2.3. Western blot analysis
Protein extracts were isolated using TRIzol Reagent (Invitrogen) fol-
lowing manufacturer's indications, clariﬁed (12,000 ×g, 15 min, 4 °C),denatured and subjected to SDS-PAGE and Western-blot. Antibodies
usedweremousemonoclonal anti-PP2A (Upstate Inc.), rabbitmonoclo-
nal anti-p-PP2A-C Y307 (Epitomics), rabbit polyclonal anti-AKT, rabbit
polyclonal anti-ERK (Cell Signaling Technology Inc.), rabbit polyclonal
anti-pAKTThr308, rabbit polyclonal anti-pERK1/2Thr202/Tyr204 (Santa Cruz
Biotechnology) and mouse monoclonal anti-βactin (Sigma). Proteins
were detected with the appropriate secondary antibodies conjugated
to alkaline phospatase (Sigma) by chemiluminescence using Tropix
CSPD and Tropix Nitro Block II (Applied Biosystems). Densitometric
analyses were performed using the Scion Image software (Scion Corpo-
ration). p-PP2A-C/PP2A-C ratios of CRC cell lines were normalized to
normal control 3. For CRC patient samples, ratios were normalized to
paired normal colonic mucosa in each CRC case.
2.4. Proliferation assay and cell viability
Cell proliferation was measured in triplicate wells by MTS assay in
96-well plates using the CellTiter 96 AQueousOne Solution Cell Prolifer-
ation Assay (Promega), following the manufacturer's indications.
2.5. PP2A phosphatase activity assays
Protein extracts were isolated from cell lysates or fresh frozen CRC
patient samples (5–10 tissue sections of 15 μm/each) using TRIzol Re-
agent (Invitrogen). PP2A assays were performed with protein extracts
(CRC cell lines: 50 μg; CRC patient samples: 100 μg) using a PP2A immu-
noprecipitation phosphatase assay kit (Millipore) and following the
manufacturer's instructions. Brieﬂy, PP2A-C was immunoprecipitated
using 4 μg of PP2A-C antibody and 25 μl Protein A agarose slurry, both
supplied by the kit. After 2 h of incubation in constant rocking, samples
werewashed 3 timeswith TBS 1X followed by one additional washwith
a ser/thr assay buffer also provided by the kit. Next, 60 μl of a diluted
phosphopeptide at 750 μM and 20 μl of ser/thr assay buffer were
added, and themix was incubated for 10min at 30 °C in a shaking incu-
bator, and then 25 μl of the mix was transferred into each well of a
96-well plate. Each measurement was performed in triplicates. 100 μl
ofMalachite GreenDetection Solutionwas added, and themixwas incu-
bated for 15 min at room temperature. Absorbance at 650 nmwas used
to calculate the amount of phosphate released (pmol) using a standard
curve (0–2000 pmol). The PP2A activity measurements in tumor sam-
ples of the CRC patients included in this study (Table 1) are relative to
paired normal colonic mucosa for each CRC patient.
2.6. Analysis of caspase activation
Quantiﬁcation of caspase 3/7 activities in untreated or forskolin-
treated CRC cells were carried out using the caspase Glo-3/7 assay kit
(Promega Corp.). Brieﬂy, 5 × 103 cells were plated in a white-walled
96-well plate, and the Z-DEVD reagent, the luminogenic caspase 3/7
substrate containing a tetrapeptide Asp-Glu-Val-Asp, was added with a
1:1 ratio of reagent to sample. After 90 min at room temperature, the
substrate cleavage by activated caspase-3 and -7, and the intensity of a
luminescent signal was measured by a FLUOstar OPTIMA luminometer
(BMG Labtech). Differences in caspase-3/7 activity in forskolin-treated
cells compared with untreated cells are expressed as fold-change in
luminescence.
2.7. Colonospheres
For the generation of colonospheres, 10,000 cells were plated in
6-well ultra-low attachment plates (Corning). CRC cell were grown
in serum-free medium DMEM/F12 + GlutMAX™-I (Gibco) containing
1% N2 (Gibco), 2% B27 (Gibco), 20 ng/ml human FGF (Sigma) and
50 ng/ml EGF (Sigma). After 7 days, plates were analyzed for
colonosphere formation. For quantiﬁcation of the number of cells per
colonosphere, colonospheres were collected and dissociated with
Table 1
Clinical and molecular characteristics of the 35 CRC patients included in the study.
Case Sex Age Site Grade T N Basal CEA Neoadjuvant
chemotherapy
High PP2A-C PP2A activity
P1a M 62 Rectum G2 T1 N0 2.7 No No Inhibited
P2a M 83 Sigma G2 T3 N2 ND No Yes Inhibited
P3a M 73 Right colon G2 T3 N0 3.1 No Yes Inhibited
P4a M 85 Rectum G2 T3 N1 4.2 No No Normal
P5a M 77 Sigma G2 T3 N0 ND No Yes Inhibited
P6a M 77 Right colon G2 T3 N2 ND No No Inhibited
P7a M 77 Left colon G2 T2 N0 1.3 No No Inhibited
P8a M 85 Left colon G2 T3 N0 2.8 No No Inhibited
P9a M 71 Rectum G2 T2 N0 ND No Yes Inhibited
P10a M 65 Sigma G2 T3 N0 2.2 No No Inhibited
P11a F 77 Rectum G2 T2 N0 3 No No Inhibited
P12a F 51 Rectum G2 T2 N0 ND No No Inhibited
P13a F 57 Left colon G2 T2 N0 0.5 No No Inhibited
P14a F 70 Rectum G1 T2 N1 129 Yes No Inhibited
P15a M 80 Right colon G2 T3 N0 4.4 No No Inhibited
P16a F 51 Rectum G2 T4 N2 ND No No Inhibited
P17a M 87 Right colon G2 T3 N0 ND No No Inhibited
P18a M 66 Right colon G1 T2 N0 3.2 No No Inhibited
P19a M 52 Transverse colon G2 T2 N0 3.9 No Yes Inhibited
P20a M 64 Sigma G2 T3 N0 1 No No Normal
P21a F 85 Right colon G2 T3 N0 ND No No Inhibited
P22 M 81 Rectum G1 T3 N2 60.4 No No Normal
P23 M 65 Transverse colon G2 T2 N0 ND No Yes Inhibited
P24 M 77 Rectum G2 T3 N0 ND No No Inhibited
P25 M 72 Transverse colon G1 T2 N0 13.2 No No Inhibited
P26 M 91 Left colon G2 T2 N0 1.9 No Yes Inhibited
P27 F 78 Right colon G1 T2 N0 14.3 No No Normal
P28 M 75 Sigma G2 T3 N0 ND No No Inhibited
P29 M 78 Left colon G2 T2 N0 1.2 No No Inhibited
P30 F 59 Left colon G2 T3 N0 ND No Yes Inhibited
P31 M 90 Right colon G1 T3 N0 ND No Yes Inhibited
P32 M 64 Left colon G2 T3 N0 1.9 No No Inhibited
P33 F 87 Left colon G1 T4 N1 ND No Yes Inhibited
P34 F 73 Right colon G2 T3 N0 1.2 No No Normal
P35 F 76 Right colon G1 T3 N0 ND No Yes Inhibited
M: male; F: female; ND: no data.
a These cases were previously included in Cristobal et al. (2014) [20].
Fig. 1.Analysis of PP2A-C in CRC cell lines.Western blot analysis of PP2A-C phosphorylation
and expression in normalmucosa and in 7 CRC cell lines, including a densitometric analysis
of the p-PP2A-C/PP2A-C ratios, which were normalized to normal control 3 (N3). N1-3:
normal mucosa.
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Neubauer chamber using a trypan blue exclusion test.
2.8. Statistical analysis
Data represented are mean of three independent experiments ± s.d.
Statistical comparisons were carried out by 2-sided t-test analyses. A
P value less than 0.05 was considered statistically signiﬁcant. Chou-
Talalay analysis was performed after 72 h of treatment using the
CompuSyn Software (ComboSyn, Inc.) and combination index (CI) was
used to determine additive/synergism calculations between forskolin
and 5-ﬂuorouracil/oxaliplatin treatments. CI b 0.90, 0.90 b CI b 1.10
and CI N 1.10were considered, respectively, synergistic, additive and an-
tagonistic effects.
3. Results
3.1. PP2A-C is hyperphosphorylated in CRC cell lines
Inhibition of the tumor suppressor PP2A has been described in sev-
eral human cancers andphosphorylation of PP2A-C at Y307 has been re-
ported to be responsible for PP2A inactivation [10]. Therefore, we ﬁrst
analyzed the p-PP2A-C Y307 status in 7 CRC cell lines and in 3 normal
colonic mucosa samples, observing an increased p-PP2A-C/PP2A-C
ratio in all the 7 CRC cell lines analyzed in comparisonwith normal con-
trols (Fig. 1). These results suggest that CRC cell lines present a reduced
PP2A activity and that its hyperphosphorylation could be a relevant
mechanism to inhibit PP2A in CRC.3.2. Forskolin leads to a reduced proliferation dependent on PP2A activation
To study the biological relevance of p-PP2A-C Y307 we assessed
proliferation of CRC cells after the treatment with the PP2A activator
forskolin in the SW480 and HT-29 cell lines. We ﬁrst conﬁrmed by
PP2A assays that forskolin activates PP2A, observing around 1.5-fold in-
crease in the PP2A activity (Fig. 2A). As a control, we pretreated SW480
and HT-29 cells with the PP2A inhibitor OA for 2 h, followed by incuba-
tionwith vehicle (DMSO) or forskolin for 48 h, observing that forskolin-
induced PP2A activity was inhibited by OA (Fig. 2A). OA was not re-
moved from the culture medium before the addition of forskolin. Simi-
lar results were obtained using DLD-1 cells (data not shown).
Fig. 2. Forskolin impairs cell proliferation via PP2A activation. (A) PP2A assays in SW480 and HT-29 cells treated with forskolin (40 μM; 48 h) and pretreated or not with OA for 2 h
(2.5 nM). (B) MTS assay showing cell viability in SW480 and HT-29 cells treated with forskolin (40 μM) alone or in combination with OA (2.5 nM); ⁎P b 0.05; ⁎⁎P b 0.01.
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a decreased proliferation in forskolin-treated SW480 and HT-29 cells
compared with vehicle-treated cells (Fig. 2B). These results were
conﬁrmed using DLD-1 cells (data not shown). In addition, weFig. 3. Forskolin-induced PP2A activation reduces colonosphere formation capability in CRC c
colonosphere after forskolin treatment (40 μM) in SW480 and HT-29 cells; ⁎P b 0.05; ⁎⁎P b 0.0observed that the antiproliferative effects of forskolin were partially
rescued by the pre-treatment with OA. Altogether, these results
show that PP2A activation by forskolin decreases proliferation in
CRC cells.ells. (A) Colonosphere formation (7 days) and (B) evaluation of the number of cells per
1.
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CRC cells
To further investigate the molecular effects of the forskolin-induced
PP2A activation in CRC, we assessed colonosphere formation in SW480
and HT-29 cells treated with forskolin. Interestingly, we observed that
forskolin led to decreased colonosphere formation ability in both the
number and size of colonospheres formed in both cell lines (Fig. 3 and
Supplementary Fig. 1). These observations were conﬁrmed in DLD-1
cells (data not shown).
Furthermore, we assessed apoptosis in SW480 and HT-29 cells after
forskolin treatment. Vehicle-treated cells were used as controls. Consis-
tent with its ability to enhance PP2A activity and impair cell growth
(Fig. 2), forskolin induced an activation of caspase 3/7 in SW480 cells
(Fig. 4A). Results were conﬁrmed in the HT-29 (Fig. 4A), and DLD-1
(data not shown) cell lines. Moreover, caspase activity decreased
when cells were pretreated with OA.
3.4. Forskolin induces changes in the phosphorylation status of PP2A targets
We next analyzed by western blot the molecular effects of the
forskolin-induced PP2A activation, observing that p-PP2A-C Y307 was
negatively affected in forskolin-treated SW480 and HT-29 cells in com-
parison with cells treated with vehicle (DMSO). Interestingly, forskolin
also decreased phosphorylation (activity) of AKT and ERK without af-
fecting their expression levels (Fig. 4B). Pretreatment with OA restored
forskolin-induced dephosphorylation in all cases. Similar results wereFig. 4. Forskolin induces caspase-dependent apoptosis together with changes in the phosphory
(DMSO), and forskolin-treated (40 μM; 48 h) alone or in combination with a pretreatment with
and expression after forskolin treatment (40 μM; 48 h) in SW480 and HT-29 cells; ⁎P b 0.05; ⁎obtained with the DLD-1 cell line (data not shown). These results indi-
cate that forskolin-induced PP2A-C dephosphorylation and activation
increases apoptosis and affects phosphorylation status of PP2A targets
in CRC cells.
3.5. Additive/synergistic effects of forskolin-induced PP2A activation with
5-FU and oxaliplatin treatments in CRC cells
In order to assess the effect of a combination between standard in-
duction chemotherapy drugs used in CRC and forskolin, we treated
CRC cells with either 5-FU or LOHP, alone or in combination with
forskolin. Interestingly, we observed that forskolin enhanced the antitu-
mor effects mediated by 5-FU (Fig. 5A) and LOHP (Fig. 5B) treatments
in both SW480 and HT-29 cell lines. These data were also conﬁrmed
in DLD-1 (data not shown). Chou-Talalay analyses showed that the
forskolin/5-FU combination has additive effects in SW480 cells (CI =
1.08). Moreover, synergistic antitumor effects were observed when
forskolin was combined with either 5-FU in HT-29 cells (CI = 00.61)
or LOHP in SW480 (CI = 0.88) and HT-29 cells (CI = 0.62). Altogether,
these results indicate that forskolin treatment potentiates antitumor ac-
tivity of either 5-FU or LOHP treatments in CRC cells.
3.6. Analysis of PP2A phosphorylation status in CRC patient samples
To further evaluate the importance of p-PP2A-C Y307 in CRC, we
studied by western blot the phosphorylation status of PP2A in 35
cases with CRC. Patient characteristics are included in Table 1.lation status of AKT and ERK. (A) Caspase 3/7 assays in SW480 and HT-29 cells untreated
OA for 2 h (2.5 nM). (B)Western blot showing PP2A-C, AKT and ERK1/2 phosphorylation
⁎P b 0.01.
Fig. 5. Forskolin shows an additive/synergistic effects with 5-FU and LOHP treatments in CRC cells. MTS assays showing the effect of forskolin (40 μM) and 5-FU (1 μM) (A) or LOHP (1 μM)
(B) alone or in combination in SW480 and HT-29 cells. Untreated cells (DMSO) were used as controls; ⁎P b 0.05; ⁎⁎P b 0.01.
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Y307 levels in tumor tissues compared with paired normal colonic mu-
cosa (Fig. 6 and Supplementary Fig. 2). PP2A assays showed low PP2A
activity in 30 out of 35 CRC patients. Of importance, PP2A was found
inhibited in all the 11 cases with high p-PP2A-C levels (Table 1). These
results would indicate that PP2A-C is hyperphosphorylated in a sub-
group of CRC patients.Fig. 6. Analysis of p-PP2A-C in CRC patients. Western blot analysis of PP2A-C phosphory-
lation and expression in CRC patient samples, including a densitometric analysis of the
p-PP2A-C/PP2A-C ratio. Ratios were normalized to paired normal colonic mucosa in
each CRC case; N: normal mucosa; T: tumor sample; ⁎CRC patients with high p-PP2A-C
levels.4. Discussion
We report here that p-PP2A-C Y307 is a recurrent alteration that
contributes to inactivate PP2A in CRC cells. The treatmentwith forskolin
increased PP2A activity, affecting proliferation, colonosphere formation
and activation of caspase 3/7 in CRC cells and leading to changes in the
activation status of AKT and ERK. Interestingly, we observed that
forskolin-induced PP2A activation showed promising therapeutic ef-
fects in combination with standard induction chemotherapy drugs
such as 5-FU or LOHP. Moreover, we conﬁrmed that PP2A-C hyper-
phosphorylation is an alteration present in a subgroup of CRC patients.
Of importance, our data provides strong evidences that p-PP2A-C
could be a promising therapeutic target in CRC.
PP2A is a well established tumor suppressor functionally inactivated
in several types of human cancer through different contributing mech-
anisms including, in the case of CRC, mutations affecting PP2A subunits
that impair the formation of the heterotrimeric PP2A complex then
inhibiting its phosphatase activity [10,16–19]. However, these muta-
tions have been reported to show a low prevalence in CRC, which sug-
gests that other different alterations could be more relevant to inhibit
PP2A in this disease. Another molecular inactivating mechanism is the
phosphorylation of PP2A-C at Y307 [10]. In fact, PP2A-C hyper-
phosphorylation has been previously described as relevant in otherma-
lignancies such as acute myeloid leukemia [12] or Alzheimer's disease
[24]. In order to evaluate the potential relevance of this mechanism in
CRC we analyzed the p-PP2A-C status in 7 CRC cell lines, observing
that all of them showed PP2A-C hyperphosphorylation, suggesting a bi-
ological signiﬁcance of this alteration in the pathogenesis of CRC.
To further investigate the importance of p-PP2A-C in CRC we used
forskolin to treat CRC cells. We considered the use of this drug because
it has previously been reported to activate PP2A in association with its
dephosphorylation [12]. Interestingly, forskolin-mediated PP2A activa-
tion induced a potent antitumoral effect in CRC cells, impairing cell
growth and colonosphere formation, and increasing activation of cas-
pase 3/7. Interestingly, we observed that forskolin-induced PP2A
1829I. Cristóbal et al. / Biochimica et Biophysica Acta 1842 (2014) 1823–1829activity and growth inhibition were partially restored by pretreatment
with the PP2A inhibitor OA indicating that the antitumor effects induced
by this drug are due preferentially to PP2A activation. However, the ab-
sence of a total restorationwould indicate that PP2Aactivation is not the
only molecular mechanism involved in the biological effects showed by
this drug, and that probably cAMP is involved since its role as an inhib-
itor of cell proliferation has been described and forskolin is a cAMP acti-
vator [25]. As expected, we observed a PP2A-C dephosphorylation after
treatment with forskolin without changes in PP2A expression,
conﬁrming that forskolin activates PP2A through p-PP2A-C Y307 de-
phosphorylation. Moreover, we observed that the molecular mecha-
nism by which forskolin is acting involves the inhibition of the AKT
and ERK, both PP2A targets, suggesting that this effect occurs via PP2A
activation. In fact, a PP2A activation has been described which leads to
similar effects on AKT and ERK activation status by the use of selenate
and FTY720 in CRC. It has been reported that selenate reduces cell
growth and induces apoptosis in DLD-1 cells. Of interest, selenate acts
by activating PP2A, which inhibits the PI3K/AKT pathway. However,
the use of selenate at very low concentrations unexpectedly promoted
epithelial to mesenchymal transition and activated AKT, probably be-
cause PP2A activation failed at this low concentrations [26]. In addition,
we recently described that FTY720-induced PP2A activation decreased
both AKT and ERK phosphorylation status in CRC cells [26]. These obser-
vations are in concordance with the results obtained here with
forskolin.
Interestingly, our results also showed that forskolin exhibits additive
antitumor effects with the standard chemotherapy reagents 5-FU and
LOHP, suggesting the use of PP2A activators such as forskolin for future
trials in combination with these standard chemotherapy drugs. To con-
ﬁrm the importance of p-PP2A-C Y307 in CRC we analyzed 35 CRC pa-
tients (paired normal colonic mucosa and tumor samples), observing
higher p-PP2A-C Y307 in 11 out of the 35 CRC patient samples, which
suggest the existence of a subgroup of CRC patients with this alteration
that would be good candidates to be treated with PP2A activators. Of
relevance, 21 out of the 35 CRC patients included in this work were pre-
viously studied by our group in a recently published work about PP2A
and its activating drug FTY720 in CRC [20]. Thus, we observe that
other PP2A inhibitory alterations (e.g. overexpression of the endoge-
nous PP2A inhibitors SET and CIP2A) can be present in CRC patients
with low p-PP2A-C levels and lead to PP2A inhibition. On the other
hand, the potential advantage of forskolin as opposed to other PP2A ac-
tivating drugs (such as FTY720) is based on its molecular mechanism of
action in CRC cells, since our group has recently reported that PP2A-C
phosphorylation at Y307 is not affected by the treatment with FTY720
in CRC cells [20]. However, we describe here that high p-PP2A-C levels
would serve to deﬁne a subgroup of CRC patients who are candidates
to be treated with PP2A activating/dephosphorylating drugs such as
forskolin.
In conclusion, we show that PP2A-C hyperphosphorylation repre-
sents a molecular mechanism to inactivate this tumor suppressor in
CRC. Of importance, our results indicate the potential use of PP2A-C de-
phosphorylating/activatingdrugs aloneor in combinationwith standard
chemotherapy agents currently used in a subgroup of CRC patients.
However, the relatively small number of CRC patients included in this
work is a limitation of the study. Therefore, further studies are needed
to fully clarify the relevance of p-PP2A-C Y0307 in CRC pathogenesis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.06.032.Funding
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